ERBB2 and neoplasm: Finally, integrate these data via AI-driven multimodal fusion to derive PAR-2 activity scores and EGCG response signatures, enabling metabotype- and tumor genotype-stratified hypothesis-testing in early human studies (e.g., anthracycline/HER2-therapy cohorts with prospective protease-axis phenotyping), thereby establishing whether EGCG-centered, PAR-2-targeted combinations can deliver true disease modification across HF–cancer continua.